Acrivon Therapeutics(ACRV.US)

Last Updated 19:00:00 ET
longbridge loading

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock

Simplywall·
US
ACRV
-3.03%
US
IBB
+0.10%
US
PBE
+0.11%
Simplywall·
US
ACRV
-3.03%
US
IBB
+0.10%
US
PBE
+0.11%

Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy

Tip Ranks·
US
ACRV
-3.03%
US
XBI
-0.69%
US
BBH
+0.68%
Tip Ranks·
US
ACRV
-3.03%
US
XBI
-0.69%
US
BBH
+0.68%

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer

Tip Ranks·
US
ACRV
-3.03%
US
XLV
+1.10%
US
BIB
+0.05%
Tip Ranks·
US
ACRV
-3.03%
US
XLV
+1.10%
US
BIB
+0.05%

Key facts: ACRV ACR-368 ORR 39%; PD-1 combo P3 planned; Q1 loss $19M

TradingView·
US
ACRV
-3.03%
US
PBE
+0.11%
US
BBH
+0.68%
TradingView·
US
ACRV
-3.03%
US
PBE
+0.11%
US
BBH
+0.68%

Acrivon Therapeutics Q1 Loss Narrows

Fidelity·
US
ACRV
-3.03%
Fidelity·
US
ACRV
-3.03%

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Unusual Whales·
US
ACRV
-3.03%
Unusual Whales·
US
ACRV
-3.03%
© 2026 Longbridge｜Disclaimer